CoChat
Sign Up
Cited by 262Schizophrenia research and treatmentFamily Caregiving in Mental IllnessMental Health and Psychiatry

The DOI matches its Crossref record; 20 of the 22 references it cites were found in a registry or an index.

Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms After a Recent First Episode of Schizophrenia: A Randomized Clinical Trial

Open access
Subotnik, Kenneth L., Casaus, Laurie R., Ventura, Joseph, Luo, John S., Hellemann, Gerhard S., Gretchen-Doorly, Denise, Marder, Stephen, Nuechterlein, Keith H.·2015·JAMA Psychiatry
DOI 10.1001/jamapsychiatry.2015.0270PMC PMC5065351
Open this paper in CoChat — free account

Abstract

IMPORTANCE: Long-acting, injectable, second-generation antipsychotic medication has tremendous potential to bring clinical stability to persons with schizophrenia. However, long-acting medications are rarely used following a first episode of schizophrenia. OBJECTIVE: To compare the clinical efficacy of the long-acting injectable formulation of risperidone with the oral formulation in the early course of schizophrenia. DESIGN, SETTING, AND PARTICIPANTS: A randomized clinical trial performed at a university-based research clinic, between 2005 and 2012. Eighty-six patients with recent onset of schizophrenia were randomized to receive long-acting injectable risperidone or oral risperidone. Half of each group was simultaneously randomized to receive cognitive remediation to improve cognitive functioning or healthy-behaviors training to improve lifestyle habits and well-being. An intent-to-treat analysis was performed between October 4, 2012, and November 12, 2014. INTERVENTIONS: A 12-month trial comparing the long-acting injectable vs oral risperidone and cognitive remediation vs healthy-behaviors training. MAIN OUTCOMES AND MEASURES: Psychotic relapse and control of breakthrough psychotic symptoms. RESULTS: Of the 86 patients randomized, 3 refused treatment in the long-acting injectable risperidone group. The psychotic exacerbation and/or relapse rate was lower for the long-acting risperidone group compared with the oral group (5% vs 33%; χ21 = 11.1; P < .001; relative risk reduction, 84.7%). Long-acting injectable risperidone better controlled mean levels of hallucinations and delusions throughout follow-up (β = -0.30; t68 = -2.6, P = .01). The cognitive remediation and healthy-behaviors training groups did not differ significantly regarding psychotic relapse, psychotic symptom control, or hospitalization rates, and there were no significant interactions between the 2 medications and the 2 psychosocial treatments. Discontinuations owing to inadequate clinical response were more common in the oral group than in the long-acting risperidone group (χ21 = 6.1; P = .01). Adherence to oral risperidone did not appear to differ before randomization but was better for the long-acting risperidone group compared with the oral group (t80 = 5.3; P < .001). Medication adherence was associated with prevention of exacerbation and/or relapse (χ21 =11.1; P = .003) and control of breakthrough psychotic symptoms (β = 0.2; t79 = 2.1; P = .04). CONCLUSIONS AND RELEVANCE: The use of long-acting injectable risperidone after a first episode of schizophrenia has notable advantages for clinical outcomes. The key clinical advantages are apparently owing to the more consistent administration of the long-acting injectable. Such formulations should be offered earlier in the course of illness. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00333177.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jamapsychiatry.2015.0270

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 22 references

2 of the 22 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Items 201–262 of 262

Related

See all

Metadata

Authors
Subotnik, K. L., Casaus, L. R., Ventura, J., Luo, J. S., Hellemann, G. S., Gretchen-Doorly, D., Marder, S., & Nuechterlein, K. H.
Affiliations
  • University of California, Los Angeles (US)
  • Department of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine at UCLA (University of California, Los Angeles)
ORCID
Venue
JAMA Psychiatry
Publisher
American Medical Association (AMA)
Published
2015-08-01
Volume
72
Issue
8
Pages
822
ISSN
2168-622X (ISSN-L)
DOI
10.1001/jamapsychiatry.2015.0270
PMC
PMC5065351
OpenAlex
W2139645720
Semantic Scholar
32694e85bf1b2e5f161e8aa329409402859aa721
Cited by
262
References
22
Citations by year
2026: 14 · 2025: 23 · 2024: 18 · 2023: 19 · 2022: 30 · 2021: 32 · 2020: 23 · 2019: 22 · 2018: 23 · 2017: 31 · 2016: 22 · 2015: 5
FWCI
21.89
Type
journal article
Language
en
Open access
Locations
  • JAMA Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
  • Janssen Scientific Affairs
  • National Institutes of Health (MH066286)
  • Genentech
  • National Institute of Mental Health (MH037705, MH-066286, R01MH037705, P50MH066286, NCT00333177)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Social Sciences › Psychology › Clinical Psychology › Family Caregiving in Mental Illness
  • Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
Keywords
long-acting injectable risperidone, first-episode schizophrenia, psychotic relapse, cognitive remediation, psychosocial interventions, medication adherence, hospitalization, relapse prevention, atypical antipsychotics, delusions and hallucinations, treatment discontinuation
MeSH terms
Administration, Oral, Combined Modality Therapy, Delayed-Action Preparations, Female, Humans, Male, Schizophrenia, Antipsychotic Agents, Health Behavior, Cognitive Behavioral Therapy, Treatment Outcome, Risperidone, Medication Adherence, Secondary Prevention, Young Adult, Early Medical Intervention

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review